According to research the global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
Don’t miss out on business opportunities in Vaccine Adjuvants Market
Browse and in-depth TOC on “Vaccine Adjuvants Market”
90 – Tables
42 – Figures
156 – Pages
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
SEPPIC (France) held the second position in the vaccine adjuvants market in 2015. This can be attributed to the company’s strong portfolio of vaccine adjuvants. The company adopts organic growth strategies such as expansions to boost its market share. For instance, SEPPIC (France) launched a production and sterile packaging unit for vaccine adjuvants and injectables by investing USD 6.66 million in Castres, France.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894